Solution offers researchers the power to perform glycan screening of large sample cohorts enabling better decisions in clone selection and cell culture optimization
January 30, 2018
Framingham, MA — SCIEX, a global leader in life science analytical technologies, today announced the launch of the new C100HT for qualitative glycan screening in biopharma. Combined with SCIEX’s award-winning fast glycan chemistry, the C100HT enables researchers challenged by time-consuming sample preparation and data analysis the ability to expand their workflow by hundreds of glycan samples per day obtaining visual actionable data without the need for time consuming interpretation.
SCIEX C100HT high throughput glycan screening technology is based on advanced capillary electrophoresis hardware armed with user-friendly software, an assay kit configured for up to 1000 separations, and a 12 capillary reagent cartridge for parallel processing of samples. Glycan acceptance criteria can be put in the intuitive analysis dashboard enabling a pass/fail result to be viewed at a glance and decisions on clone selection and cell line optimization to be made in real-time. The C100HT comes complete with a mobile lab bench allowing researchers full flexibility within their own facilities to locate the analytics at the point of decision making.
The C100HT sample preparation chemistry allows preparation of 96 samples in less than 2 hours enabling clones to be selected from large sample populations quickly and cell culture optimization to be performed in real time to significantly increase the likelihood of selecting the best clones and manufacturing conditions. Automated glycan identification eliminates the need for tedious glycan database searches, thus minimizing the potential for human error and optimizing the workflow.
“Being able to select clones and cell culture conditions using information other than titer allows for an enhanced capability where larger populations can be screened, providing better information with which to choose and develop impactful biologics,” said Mark Lies, Senior Product Manager at SCIEX. “Glycan screening is an important part of the process, but it has been limited by how many clones can be screened, not to mention the ensuing data. The C100HT represents a solution to this challenge and includes simplified sample preparation, an instrument of straight forward design, and meaningful visual data analysis, enabling researchers to improve their workflow throughput wherever their samples are generated, leading to fast answers for fast decision making.”
SCIEX’s Fast Glycan Labeling and Analysis technology was awarded the 2016 BioProcess International (BPI) “Award for Best Technology Application – Analytical” for demonstrating increased functionality in novel combinations with other analytical technologies.
Learn more about the new C100HT.
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company’s global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com
For research use only. Not for use in diagnostic procedures. RUO-MKT-12-7094-A
AB Sciex is operating as SCIEX.
© 2018 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.